http://localhost:8080/xmlui/handle/123456789/7243 2026-04-18T09:12:20Z 2026-04-18T09:12:20Z SOLANKI, KHUSHBU http://localhost:8080/xmlui/handle/123456789/8190 2020-11-30T09:10:52Z 2018-05-01T00:00:00Z

Formulation, characterization and evaluation of wafer containing antimicrobial agent for wound infection SOLANKI, KHUSHBU The aim of present research work is to formulate wafer containing antimicrobial agent for wound infection. Wound is an infectious diseases which can be the result of colonization of the body by various microorganisms. The main microorganisms on skin are grampositive cocci (probably staphylococci e.g. Methicillin resistant staphylococcus aureus). The formulation has sustained release of vancomycin hydrochloride with antibacterial effect at wound site.The wafer containing antimicrobial agent was prepared by lyophilization method. FTIR was performed to study drug-excipient compatibility. Analytical method was developed by UV-spectroscopy. Optimization of formulation was done by 32 full factorial design. Wafer containing antimicrobial agent was evaluated for viscosity, % drug content, swelling capacity, water uptake study, In-vitro % cumulative drug release study, scanning electron microscopy (SEM), In-vivo wound healing study. Drug content and swelling capacity of optimized batch A3 were 98.06±0.053 % and 852.23± 0.036 % respectively. The % cumulative drug release of optimized batch A3 was 93.78±0.28% up to 16 hrs. Stability study data of optimized batch A3 showed, wafer was stable at accelerated condition (40°C± 2°C and 75± 5 % RH) after 2 months.From the result it was concluded that the wafer containing antimicrobial agent had maximum drug release in 16 hrs with good wound healing effect as well as good stability. This research work proves that the optimized wafer formulation containing vancomycin hydrochloride is potential drug delivery device against wound infection. For Full Thesis Kindly contact to respective Library

2018-05-01T00:00:00Z ANTENEH, TAMIRAT http://localhost:8080/xmlui/handle/123456789/7244 2020-11-06T10:51:35Z 2018-05-01T00:00:00Z

Effect of empagliflozin and its combination with metformin in experimentally induced myocardial infraction in diabetic rats. ANTENEH, TAMIRAT Objective: The objective of the present study was to evaluate cardio-protective effect of sodium glucose co-transporter-2 inhibitor alone and its combination with metformin in experimentally induced myocardial infarction in diabetic rats. Method: Type 2 Diabetes was induced in rats by a single intraperitoneal (i.p) injection of Streptozotocin (65 mg/kg, STZ) in overnight fasting rats followed by the i.p administration of Nicotinamide (120 mg/kg, NIC) after 15 minutes. Animals were divided into five groups of each six animals. Group I served as normal control and received vehicle (0.5% hydroxy ethyl cellulose) for 4 weeks and normal saline subcutaneously on 29th and 30th days. Group II served as diabetic-myocardial control and received STZ-NIC (65-120mg/kg, i.p) and Isoproterenol (85mg/kg, sc) on 29th and 30th days. Group III received STZ-NIC, ISO and Empagliflozin 5mg/kg, po for 4 weeks. Group IV received STZ-NIC, ISO and Empagliflozin 10mg/kg, po for 4 weeks. Group V received STZ-NIC, ISO and Empagliflozin 5mg/kg + Metformin 50mg/kg, po for 4 weeks. Group IV received STZ-NIC, ISO and Empagliflozin 10mg/kg, po for 4 weeks. Group V received STZ-NIC, ISO and Empagliflozin 5mg/kg + Metformin 50mg/kg, po for 4 weeks. At the end of the treatment period, rats were anaesthetized with anaesthetic ether after 24hr of final drugs dose administration and then; blood was collected from the retro-orbital plexus for estimation of different biochemical parameters like blood glucose (BG), cratine kinase MB (CK-MB), lactate dehydrogenase (LDH), aspartate transaminase (AST), Troponin I and lipid profile. Result and Discussion: Animals treated with the combination of Empagliflozin and Metformin showed significant inhibition in the elevated level of BG, CK-MB, LDH, AST, Troponin and lipid profile in diabetic animals compared to diabetic control (Group II) animals and Group III and IV animals receiving only Empagliflozin 5 mg/kg and 10 mg/kg respectively. Conclusion: Empagliflozin by acting through sodium glucose co-transporter-2 and Metformin by acting through activation of the 5’-adenosine monophosphate-activated protein kinase (AMPK) pathway, when used in combination could have beneficial effects in preventing cardiovascular diseases (CVD) in type 2 diabetes as compared to individual drugs. It was found to decrease cardiovascular risk factors synergistically by Empagliflozin and Metformin combination in type 2 diabetes mellitus. For Full Thesis Kindly contact to respective Library

2018-05-01T00:00:00Z